Introduction: Those Were The Days; A Walk Down NNVC Lane
On Tuesday, August 30, 2005, I introduced the readers of my AllAllan blog to NanoViricides (NNVC), a penny stock trading on the pink sheets. Although it was under 10 cents when I first introduced the shares to my readers, the "split adjusted" price shown in this chart below is about $5.00. The hook: Bird Flu - NNVC was all over it. During the next 6-8 months these shares soared, in fact, so much so that many of my current subscribers to Blue Line Trading have remained readers and subscribers, ever since. (Thank you.)
Note how well our 50% trailing profit stop would have worked in early 2006. This is why recognizing an opportunity and managing the exit are inseparable.
The special situation then was penny stock-bird flu-biotechnology. The AI-Genomics theme may rhyme with the bird flu mania of the early 2000's, but in so many ways it is much bigger, its scope more universal and its potential much greater than that which sent NNVC soaring in 2005-2006. FWIW, from our entry into NNVC in late summer, 2005, at around $5, split adjusted, the maximum gain was 5,150% into the following March. Even a fraction of that kind of return as the AI-Genomics science unfolds in the years ahead will be well worth our diligence in identifying and investing in the runners in this sector.
As the NNVC chart so clearly shows, getting in early created the opportunity; managing the exit determined how much we kept. I see the potential for substantial opportunities as AI and genomics develop over the coming years. How much of that potential becomes a profitable trade will depend on our entries, our exits, and which companies actually deliver.
A more recent example was Tesla. In December 2019, I selected TSLA as my stock of the year for 2020 and recommended the January 2021 $420 calls at $35. You can revisit that original reasoning in “Game Changer,” linked here. Those calls, if held until expiration ,topped off north of 10,000%. Even a :"just in case" remainder position paid off big time:
"In Dec, 2019 I sent out the "Game Changer" white paper in which we initiated a Long position in TSLA at $70. In the ensuing 13 months TSLA rose to $900, a gain of 12X the original investment. The recommended Jan 2021 $84 LEAPS rose from $740 at expiration, a gain of approximately 10,000%,
*all above prices adjusted for 5:1 stock split effective Aug 31, 2020.
The value of revisiting these calls is seeing what we recognized before the outcome was known: a developing theme and a specific way to participate.
What makes those experiences relevant today is the way they began: a developing theme, companies positioned to participate, and price action that gave us a reason to pay attention.
AI Meets Genomics: One Theme, Two Ways to Participate
This begins the new content section that was sent out to Blue Line Trading System subscribers, this weekend. If you are not currently subscribed, take advantage of my offer of 1/2 off first month to either Premium or PRO (All PRO subscriptions include Premium membership). In it are recommended calls on two new stocks and an updated review of our #1 best bet going into the 4th quarter of 2026 and onto 2027.
Warning: Can be habit forming.